Alkermes plc
Alkermes plc (ALKS) Straddle
ALKS straddle scan found 92 qualifying long straddle setups on the previous trading day. Probability of profit reaches up to 60.9%.
Read more
Trading a ALKS straddle lets you take a pure volatility position on Alkermes plc without committing to a direction. Alkermes plc's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate ALKS straddle pricing in real time and find the moments when expected moves are mispriced.
A long straddle on ALKS profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when Alkermes plc stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the ALKS straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases.
The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Earnings, product cycles, macro prints — any time volatility itself is the trade, the ALKS straddle is the cleanest expression of that view. Our scanner prices every ALKS straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a ALKS straddle into a catalyst or short a ALKS straddle to harvest decay, the options straddle setups that matter are all in one place.
| Jan 21, 2028 | 80.00 | $38.25 | 493 | 84% | 60.9% | $118.25 | $41.75 | 0 |
| Jan 21, 2028 | 75.00 | $34.80 | 493 | 84% | 60.0% | $109.80 | $40.20 | 0 |
| Jan 21, 2028 | 70.00 | $31.00 | 493 | 84% | 60.0% | $101.00 | $39.00 | 0 |
| Jan 21, 2028 | 65.00 | $28.25 | 493 | 84% | 58.5% | $93.25 | $36.75 | 0 |
| Jan 21, 2028 | 60.00 | $25.80 | 493 | 84% | 56.7% | $85.80 | $34.20 | 0 |
| Jan 21, 2028 | 55.00 | $24.00 | 493 | 84% | 53.8% | $79.00 | $31.00 | 0 |
| Dec 18, 2026 | 60.00 | $16.08 | 94 | 84% | 52.8% | $76.08 | $43.93 | 8 |
| Feb 19, 2027 | 60.00 | $18.48 | 157 | 84% | 52.7% | $78.48 | $41.53 | 0 |
| Jan 15, 2027 | 65.00 | $21.18 | 122 | 84% | 52.7% | $86.18 | $43.83 | 0 |
| Jan 15, 2027 | 60.00 | $17.25 | 122 | 84% | 52.5% | $77.25 | $42.75 | 0 |
As of September 16, 2026
Find the right straddle before volatility moves
Track ALKS straddle pricing across expirations, filter by IV rank and breakeven points, and build a setup that fits your view before the move happens.
Start your 14-day free trial→